7 registrations that name ginkgo biloba as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 7 registrations
Status
Phase
All 7 registrations
RecruitingNCT06704334
The Study of Ginkgo Leaf Dropping Pills and Huperzine A Injection Combined With Median Nerve Electrical Stimulation in the Treatment of Cognitive Impairment After Brain Injury
Phase 4
Wanbangde Pharmaceutical Group Co., LTD
About 50 people
Started Apr 1, 2024
In plain words A Phase 4 study of ginkgo biloba in people 18 to 80, run by Wanbangde Pharmaceutical Group Co., LTD. It plans to enroll about 50 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Cognitive Impairment After Brain Injury.
Be over 18 years old
Residual cognitive impairment due to brain injury
No previous history of brain-related diseases except this one
The exclusion criteria are on the listing.
What it tests, as registered
Median nerve electrical stimulation treatment; Huperzine A injection; Ginkgo leaf dropping pill
Registered summary
This study will conduct a single-center clinical trial to explore the initial therapeutic effect of ginkgo biloba dropping pills, huperzine A injection and median nerve electrical stimulation in patients with cognitive impairment.
Where, as registered
No US site; China (1).
Not yet recruitingNCT06861426
Effectiveness of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke
Observational
Ying Gao
About 4,460 people
Starts Mar 1, 2025 (estimated)
In plain words An observational study of ginkgo biloba in people 18 and older, run by Ying Gao. It plans to enroll about 4,460 people at 10 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Acute Ischemic Stroke.
aged ≥18 years, regardless of gender
within 48 hours of stroke onset of ischemic stroke
patient or their legally authorized representative (LAR) has signed informed consent or legally authorized oral consent with documentation
The exclusion criteria are on the listing.
What it tests, as registered
Ginkgo Diterpene Lactone Meglumine
Registered summary
The primary purpose of this study is to investigate the effectiveness of Ginkgo Diterpene Lactone Meglumine (GDLM) for patients with acute ischemic stroke (AIS) in real-world settings.
Where, as registered
No US site; China (10).
Not yet recruitingNCT06140888
Effect of Ginkgo Biloba Extract on Cognitive Function in Acute Ischemic Stroke
No phase
Yi Yang
About 356 people
Starts Mar 15, 2024 (estimated)
In plain words A study of ginkgo biloba in people 18 and older, run by Yi Yang. It plans to enroll about 356 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Acute Ischemic Stroke.
Patients with a definitive clinical diagnosis of acute ischemic stroke;
Age≥18 years, regardless of sex；
Primary education level or higher; baseline MoCA score of 10-25 points;
Able to complete cognitive scale scoring;
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Ginkgo Biloba Extract
Registered summary
The purpose of this study is to determine the effect of ginkgo biloba extract on cognitive function in acute ischemic stroke.
Where, as registered
No sites listed yet.
Not yet recruitingNCT06813274
Multicenter RCT of Eye-Brain Imaging in Diabetes Neurovascular Coupling
Phase 2
Hejiang Ye
About 160 people
Starts Jan 1, 2026 (estimated)
In plain words A Phase 2 study of ginkgo biloba in people 18 to 70, run by Hejiang Ye. It plans to enroll about 160 people at 3 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Diabetes Mellitus; Diabetic Retinopathy; Cognitive Impairment; Neurovascular Coupling.
Participants who comply with the diagnostic criteria for DM according to the World Health Organization in 1999.
Participants who fulfill the diagnostic criteria for diabetic NCI.
This study intends to take the critical pathological mechanism of diabetic neurovascular coupling injury (NCI) as the starting point and utilize multi-modal imaging (MMI) technology of the eyes and brain as a means to conduct in-depth, integrated, and interdisciplinary research with Traditional Chinese Medicine (TCM) syndrome studies. The aim is to establish diagnostic and therapeutic standards for diabetic NCI, based on Eye-Brain Multimodal Imaging technology, providing objective and quantitative evidence for early disease diagnosis and therapeutic effect evaluation. The full summary is on the listing.
Where, as registered
No US site; China (3).
Not yet recruitingNCT07579689
Effects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment
Phase 4
Hanyang University
About 120 people
Starts Jun 2026 (estimated)
In plain words A Phase 4 study of ginkgo biloba in people 20 and older, run by Hanyang University. It plans to enroll about 120 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 20 and older. Conditions: Mild Cognitive Impairment; Alzheimer's Disease.
Age 20 years or older
Clinical Dementia Rating (CDR) score of 0.5
Patients clinically indicated for treatment with Ginkgo biloba extract
The exclusion criteria are on the listing.
What it tests, as registered
Ginkgo Biloba Extract 240 mg; Placebo
Registered summary
This study evaluates the effects of Ginkgo biloba on blood biomarkers related to Alzheimer's disease in patients with mild cognitive impairment. Participants will be randomly assigned to receive either Ginkgo biloba or a placebo for 6 months. Changes in blood biomarkers, including p-tau217 and neurofilament light (NfL), as well as cognitive function, will be assessed to determine whether Ginkgo biloba may influence disease-related biological processes.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07709312
the Effect of Ginkgo Biloba on Rheumatoid Arthritis Patients
Phase 2 and 3
Ain Shams University
About 50 people
Starts Oct 15, 2026 (estimated)
In plain words A Phase 2 and 3 study of ginkgo biloba in people 18 and older, run by Ain Shams University. It plans to enroll about 50 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Rheumatoid Arthritis (RA); Manegmentof Rheumatoid Arthritis.
Adult patients (older than 18 years) -
With moderate to high disease activity defined as DAS-28 score ≥ 3.2
Patients receiving stable regimen of one or more csDMARDs for the past 6 months Exclusion criteria
Patients with known hypersensitivity to Ginkgo biloba
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Ginkgo Biloba Extract (120 mg ) manufuctured by EMA PHARM
Registered summary
this study aims to measure The Effect of Gingko Biloba on the Clinical Outcome of Rheumatoid Arthritis Patients ,the outcomes are hsCRp,calprotectin,DAS-28,HAQ-DI
Where, as registered
No sites listed yet.
Not yet recruitingNCT07166835
Exploring the Cognitive Benefits of a Blackcurrant-Based Supplement in Normobaric Hypoxia
No phase
Leeds Beckett University
About 27 people
Starts Sep 1, 2025 (estimated)
In plain words A study of ginkgo biloba in male participants 18 to 35, run by Leeds Beckett University. It plans to enroll about 27 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 to 35; healthy volunteers accepted. Conditions: Cognitive Performance; Executive Function (Cognition); Working Memory; Hypoxia Induced Cognitive Impairment; Mood.
Willing and able to provide written informed consent (in English)
Aged 18-35
Male
Residing at a low altitude (<500m)
The exclusion criteria are on the listing.
What it tests, as registered
Nootropics (ginkgo biloba, nicergoline, piracetam, or others); Placebo
Registered summary
This study investigates the cognitive effects of Ārepa, a blackcurrant-based drink, under simulated high-altitude conditions (4,500m normobaric hypoxia for \~180 minutes). Using a double-blind, randomised, placebo-controlled crossover design, participants will consume either the nootropic blackcurrant-based drink or a taste-matched placebo. Cognitive testing (\~80 minutes) includes Trail-making, Stroop, N-back, Serial 7s/3s, and RVIP tasks. Physiological measures (heart rate, SpO₂, blood) and biomarkers (MAO-B, BDNF, hsCRP, S100B, Prolactin, C3G, Sarmentosin) will be assessed. The full summary is on the listing.